Natera, Inc. (NTRA)
Largest Insider Buys in Sector
NTRA Stock Price History Chart
NTRA Stock Performance
About Natera, Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro …
Insider Activity of Natera, Inc.
Over the last 12 months, insiders at Natera, Inc. have bought $0 and sold $146.64M worth of Natera, Inc. stock.
On average, over the past 5 years, insiders at Natera, Inc. have bought $3.98M and sold $81.75M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 219,820 shares for transaction amount of $6.32M was made by Rabinowitz Matthew () on 2022‑05‑12.
List of Insider Buy and Sell Transactions, Natera, Inc.
| 2024-12-18 | Sale | CO-FOUNDER | 5,700 0.0047% | $167.25 | $953,337 | 0.00% | ||
| 2024-12-13 | Sale | EXECUTIVE CHAIRMAN | 160,000 0.121% | $165.74 | $26.52M | +1.00% | ||
| 2024-12-10 | Sale | director | 1,767 0.0014% | $170.24 | $300,808 | +0.23% | ||
| 2024-12-09 | Sale | PRESIDENT, CLINICALDIAGNOSTICS | 4,858 0.0036% | $166.59 | $809,312 | -0.74% | ||
| 2024-12-02 | Sale | director | 87,473 0.066% | $169.12 | $14.79M | -1.07% | ||
| 2024-11-26 | Sale | EXECUTIVE CHAIRMAN | 2,000 0.0063% | $164.17 | $328,348 | -0.07% | ||
| 2024-11-25 | Sale | EXECUTIVE CHAIRMAN | 2,000 0.0065% | $168.51 | $337,028 | +2.36% | ||
| 2024-11-19 | Sale | director | 9,682 0.0298% | $159.98 | $1.55M | +3.67% | ||
| 2024-11-15 | Sale | CEO AND PRESIDENT | 4,728 0.0133% | $146.41 | $692,209 | +14.91% | ||
| 2024-11-15 | Sale | director | 37,230 0.1045% | $146.11 | $5.44M | +14.91% | ||
| 2024-11-14 | Sale | director | 2,212 0.0067% | $158.53 | $350,672 | +11.04% | ||
| 2024-11-13 | Sale | CO-FOUNDER | 36,300 0.108% | $154.86 | $5.62M | +4.24% | ||
| 2024-11-08 | Sale | CO-FOUNDER | 5,700 0.0143% | $130.78 | $745,471 | +24.72% | ||
| 2024-10-31 | Sale | CHIEF FINANCIAL OFFICER | 1,866 0.0045% | $126.45 | $235,956 | +37.61% | ||
| 2024-10-29 | Sale | CHIEF FINANCIAL OFFICER | 754 0.0017% | $119.93 | $90,427 | +33.44% | ||
| 2024-10-28 | Sale | SEC. AND CHIEF LEGAL OFFICER | 1,057 0.0024% | $118.21 | $124,949 | +37.04% | ||
| 2024-10-28 | Sale | CEO AND PRESIDENT | 3,960 0.009% | $118.21 | $468,114 | +37.04% | ||
| 2024-10-28 | Sale | PRESIDENT, CHIEF BUS. OFFICER | 929 0.0021% | $118.21 | $109,818 | +37.04% | ||
| 2024-10-28 | Sale | PRESIDENT, CLINICALDIAGNOSTICS | 1,196 0.0027% | $118.21 | $141,380 | +37.04% | ||
| 2024-10-28 | Sale | CHIEF FINANCIAL OFFICER | 1,238 0.0028% | $118.21 | $146,345 | +37.04% |
Insider Historical Profitability
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN | 2389180 1.8097% | $161.88 | 1 | 71 | +52.44% |
| BOTHA ROELOF | director | 1224787 0.9277% | $161.88 | 2 | 2 | +4.55% |
| HEALY JAMES | director | 0 0% | $161.88 | 3 | 2 | <0.0001% |
| Steuart John | director | 0 0% | $161.88 | 1 | 1 | <0.0001% |